title: Vesicant characteristics of oxaliplatin following antecubital extravasation.
abstract: Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.
authors.affiliation: Department of Orthopaedic Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Kennedy
authors.forename: J P
authors.initials: JP
authors.lastname: Donahue
authors.forename: B
authors.initials: B
authors.lastname: Hoang
authors.forename: P J
authors.initials: PJ
authors.lastname: Boland
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005260:Female; D006801:Humans; D007509:Irritants; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D007509:Irritants; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin